FDA Seeks Pediatric Review Of Four Cancer Drugs With Hard-to-study Populations
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC's pediatric subcommittee will consider pediatric development plans and the formulation of written requests for Allos' Folotyn, Amgen's Prolia, Eisai's eribulin and Pfizer's crizotinib.